GPT-Rosalind: OpenAI Launches Specialized AI for Life Sciences

On April 16, OpenAI launched GPT-Rosalind, a frontier reasoning model purpose-built for drug discovery, genomics, and protein engineering — named after pioneering chemist Rosalind Franklin.

Key highlights: • GPT-Rosalind is fine-tuned across genomics, protein engineering, and chemistry, supporting hypothesis generation, experimental planning, and multi-step scientific workflows. • On BixBench (real-world bioinformatics), it achieved the leading performance among models with published scores; it also outperformed GPT-5.4 on 6 of 11 LABBench2 tasks. • Launching as a research preview for qualified Enterprise customers including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. • A new Codex research plugin connects scientists to 50+ data sources and tools for accelerated research workflows.

Why it matters: This is the clearest signal yet that the era of one-size-fits-all frontier models is ending. Specialization at the reasoning layer is how AI crosses from general productivity into genuine scientific value. Drug discovery timelines — historically measured in decades — could compress dramatically.